Skin Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major skin neoplasms markets reached a value of US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.91% during 2024-2034.
The skin neoplasms market has been comprehensively analyzed in IMARC's new report titled "Skin Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Skin neoplasms are abnormal growths of skin cells that can be potentially cancerous. Some of the common symptoms are the development of new or changing skin lesions, such as moles or growths, that may exhibit irregular borders, asymmetry, varying colors, or an increase in size. Numerous other indications may include persistent sores that do not heal, scaly or crusty patches on the skin, itching, tenderness, pain, bleeding from a skin lesion, etc. In advanced cases, skin neoplasms may manifest with various symptoms, such as enlarged lymph nodes, weight loss, fatigue, etc. The diagnosis typically involves a combination of clinical examination, imaging techniques, and a biopsy. A dermatologist or healthcare professional will evaluate the skin lesion, noting its size, shape, color, and any associated symptoms. Dermoscopy, a non-invasive imaging technique, may be used to examine the lesion in greater detail. If a suspicious or concerning lesion is identified, a biopsy will be performed to obtain a tissue sample for further analysis. Additional diagnostic tests, such as imaging studies or lymph node biopsies, may be done if there are indications of advanced disease or spread to surrounding tissues.
The increasing cases of exposure to UV radiation from the sun or artificial sources, such as tanning beds, resulting in the damage of DNA in skin cells, are primarily driving the skin neoplasms market. In addition to this, the rising prevalence of various associated risk factors, including weakened immune systems, exposure to carcinogens, chronic skin inflammation, certain genetic syndromes like xeroderma pigmentosum, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of cryotherapy, which involves the application of extreme cold temperatures to destroy abnormal or cancerous cells, is further bolstering the market growth. Apart from this, the escalating utilization of Mohs micrographic surgery, since it allows for the precise removal of cancer cells and conservation of as much healthy tissues as possible, is acting as another significant growth-inducing factor. Additionally, the introduction of advanced imaging technologies, such as reflectance confocal microscopy (RCM) and optical coherence tomography (OCT), that aid in enabling non-invasive examination and evaluation of skin lesions at a cellular level, is expected to drive the skin neoplasms market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the skin neoplasms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for skin neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the skin neoplasms market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the skin neoplasms market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the skin neoplasms market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current skin neoplasms marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the skin neoplasms market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the skin neoplasms market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the skin neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of skin neoplasms across the seven major markets?
What is the number of prevalent cases (2018-2034) of skin neoplasms by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of skin neoplasms by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with skin neoplasms across the seven major markets?
What is the size of the skin neoplasms patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of skin neoplasms?
What will be the growth rate of patients across the seven major markets?
Skin Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for skin neoplasms drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the skin neoplasms market?
What are the key regulatory events related to the skin neoplasms market?
What is the structure of clinical trial landscape by status related to the skin neoplasms market?
What is the structure of clinical trial landscape by phase related to the skin neoplasms market?
What is the structure of clinical trial landscape by route of administration related to the skin neoplasms market?
The skin neoplasms market has been comprehensively analyzed in IMARC's new report titled "Skin Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Skin neoplasms are abnormal growths of skin cells that can be potentially cancerous. Some of the common symptoms are the development of new or changing skin lesions, such as moles or growths, that may exhibit irregular borders, asymmetry, varying colors, or an increase in size. Numerous other indications may include persistent sores that do not heal, scaly or crusty patches on the skin, itching, tenderness, pain, bleeding from a skin lesion, etc. In advanced cases, skin neoplasms may manifest with various symptoms, such as enlarged lymph nodes, weight loss, fatigue, etc. The diagnosis typically involves a combination of clinical examination, imaging techniques, and a biopsy. A dermatologist or healthcare professional will evaluate the skin lesion, noting its size, shape, color, and any associated symptoms. Dermoscopy, a non-invasive imaging technique, may be used to examine the lesion in greater detail. If a suspicious or concerning lesion is identified, a biopsy will be performed to obtain a tissue sample for further analysis. Additional diagnostic tests, such as imaging studies or lymph node biopsies, may be done if there are indications of advanced disease or spread to surrounding tissues.
The increasing cases of exposure to UV radiation from the sun or artificial sources, such as tanning beds, resulting in the damage of DNA in skin cells, are primarily driving the skin neoplasms market. In addition to this, the rising prevalence of various associated risk factors, including weakened immune systems, exposure to carcinogens, chronic skin inflammation, certain genetic syndromes like xeroderma pigmentosum, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of cryotherapy, which involves the application of extreme cold temperatures to destroy abnormal or cancerous cells, is further bolstering the market growth. Apart from this, the escalating utilization of Mohs micrographic surgery, since it allows for the precise removal of cancer cells and conservation of as much healthy tissues as possible, is acting as another significant growth-inducing factor. Additionally, the introduction of advanced imaging technologies, such as reflectance confocal microscopy (RCM) and optical coherence tomography (OCT), that aid in enabling non-invasive examination and evaluation of skin lesions at a cellular level, is expected to drive the skin neoplasms market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the skin neoplasms market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for skin neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the skin neoplasms market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the skin neoplasms market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the skin neoplasms market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current skin neoplasms marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the skin neoplasms market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the skin neoplasms market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the skin neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of skin neoplasms across the seven major markets?
What is the number of prevalent cases (2018-2034) of skin neoplasms by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of skin neoplasms by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with skin neoplasms across the seven major markets?
What is the size of the skin neoplasms patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of skin neoplasms?
What will be the growth rate of patients across the seven major markets?
Skin Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for skin neoplasms drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the skin neoplasms market?
What are the key regulatory events related to the skin neoplasms market?
What is the structure of clinical trial landscape by status related to the skin neoplasms market?
What is the structure of clinical trial landscape by phase related to the skin neoplasms market?
What is the structure of clinical trial landscape by route of administration related to the skin neoplasms market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SKIN NEOPLASMS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SKIN NEOPLASMS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SKIN NEOPLASMS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SKIN NEOPLASMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SKIN NEOPLASMS - UNMET NEEDS
10 SKIN NEOPLASMS - KEY ENDPOINTS OF TREATMENT
11 SKIN NEOPLASMS - MARKETED PRODUCTS
11.1 List of Skin Neoplasms Marketed Drugs Across the Top 7 Markets
11.1.1 Aldara (Imiquimod ) - 3M Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Erivedge (Vismodegib) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SKIN NEOPLASMS - PIPELINE DRUGS
12.1 List of Skin Neoplasms Pipeline Drugs Across the Top 7 Markets
12.1.1 IFx-Hu2.0 - Morphogenesis
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NT-I7 - NeoImmuneTech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LTX315 - Lytix Biopharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ANV 419 - Anaveon
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Hiltonol - Oncovir
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SKIN NEOPLASMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SKIN NEOPLASMS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SKIN NEOPLASMS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Skin Neoplasms - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Skin Neoplasms - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Skin Neoplasms - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Skin Neoplasms - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Skin Neoplasms - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Skin Neoplasms - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Skin Neoplasms - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Skin Neoplasms - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Skin Neoplasms - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Skin Neoplasms - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Skin Neoplasms - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Skin Neoplasms - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Skin Neoplasms - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Skin Neoplasms - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Skin Neoplasms - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Skin Neoplasms - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Skin Neoplasms - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Skin Neoplasms - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Skin Neoplasms - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Skin Neoplasms - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Skin Neoplasms - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Skin Neoplasms - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Skin Neoplasms - Access and Reimbursement Overview
16 SKIN NEOPLASMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SKIN NEOPLASMS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SKIN NEOPLASMS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SKIN NEOPLASMS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SKIN NEOPLASMS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SKIN NEOPLASMS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 SKIN NEOPLASMS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SKIN NEOPLASMS - UNMET NEEDS
10 SKIN NEOPLASMS - KEY ENDPOINTS OF TREATMENT
11 SKIN NEOPLASMS - MARKETED PRODUCTS
11.1 List of Skin Neoplasms Marketed Drugs Across the Top 7 Markets
11.1.1 Aldara (Imiquimod ) - 3M Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Erivedge (Vismodegib) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SKIN NEOPLASMS - PIPELINE DRUGS
12.1 List of Skin Neoplasms Pipeline Drugs Across the Top 7 Markets
12.1.1 IFx-Hu2.0 - Morphogenesis
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NT-I7 - NeoImmuneTech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LTX315 - Lytix Biopharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ANV 419 - Anaveon
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Hiltonol - Oncovir
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SKIN NEOPLASMS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SKIN NEOPLASMS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SKIN NEOPLASMS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Skin Neoplasms - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Skin Neoplasms - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Skin Neoplasms - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Skin Neoplasms - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Skin Neoplasms - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Skin Neoplasms - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Skin Neoplasms - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Skin Neoplasms - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Skin Neoplasms - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Skin Neoplasms - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Skin Neoplasms - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Skin Neoplasms - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Skin Neoplasms - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Skin Neoplasms - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Skin Neoplasms - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Skin Neoplasms - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Skin Neoplasms - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Skin Neoplasms - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Skin Neoplasms - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Skin Neoplasms - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Skin Neoplasms - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Skin Neoplasms - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Skin Neoplasms - Access and Reimbursement Overview
16 SKIN NEOPLASMS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SKIN NEOPLASMS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SKIN NEOPLASMS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
